Maven Capital Partners, one of the UK’s most active private equity houses, has invested a further £500,000 in GENinCode, a genetic testing company specialising in the risk assessment and prediction of cardiovascular disease. This funding package comes as the company completes its IPO, raising an additional £17 million gross and listing on AIM with a market capitalisation of £42.2 million.